In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...